Search results
-
Hilti Fleet Management (B): Towards a New Business Model (Spanish Version)
Casadesus-Masanell, Ramon; Gassmann, Oliver; Sauer, RomanCase HBS-719S19StrategyLos tacleadas (B) de casos el proceso de implementación y la escala de gestión de flotas en los últimos años. Por último, el caso explora los desafíos actuales que enfrenta el IMC.Starting at €5.74
-
eBay, Inc. and Amazon.com (A) (Spanish version)
Casadesus-Masanell, Ramon; Thaker, AnantCase HBS-714S09StrategyThis case has been designed to explore strategic interactions among organizations with different business models. The case considers how a competitor successfully challenged the incumbent in a platform market defined by strong network effects and high switching costs. The case allows students to assess the advantages and disadvantages of eBay's platform business model in comparison to Amazon's retail business model; to evaluate business model per...Starting at €8.20
-
Coursera
Casadesus-Masanell, Ramon; Kim, HyunjinCase HBS-714412-EStrategyBy providing free and open-access online courses at a large scale, Massive Open Online Course (MOOC) platforms seek to innovate the business models of the traditional higher education industry. In a little over a year, Coursera had grown at a rapid rate to emerge as a leader of the MOOCs in terms of the number of student enrollments, courses, and partners. The case examines two aspects of these developments in the industry: (1) What choices did C...Starting at €8.20
-
Uber and the Taxi Industry (A)
Casadesus-Masanell, Ramon; Mackenzie, Ian W; Dadiomov, DimitriCase HBS-715433-EStrategyStarting at €8.20
-
UberX & Lyft (B)
Casadesus-Masanell, Ramon; Mackenzie, Ian W; Dadiomov, DimitriCase HBS-715434-EStrategySupplement case for 715433.Starting at €5.74
-
Palm (B): 2001
Casadesus-Masanell, Ramon; Boudreau, Kevin; Mitchell, JordanCase HBS-708515-EThis case series looks at three important inflection points in Palm's history that relate to decisions about its platform: when the company was debating whether to open its operating system (OS) for licensing to third-party hardware manufacturers; 2001, when the company was deciding whether to split into two separate companies; and, 2005, when the company was migrating from its own OS into Linux. (The last part, set in 2008, is an epilogue). By l...Starting at €5.74
-
Palm (C): 2005
Casadesus-Masanell, Ramon; Boudreau, Kevin; Mitchell, JordanCase HBS-708516-EThis case series looks at three important inflection points in Palm's history that relate to decisions about its platform: when the company was debating whether to open its operating system (OS) for licensing to third-party hardware manufacturers; 2001, when the company was deciding whether to split into two separate companies; and, 2005, when the company was migrating from its own OS into Linux. (The last part, set in 2008, is an epilogue). By l...Starting at €5.74
-
Palm (D): Epilogue as of 2008
Casadesus-Masanell, Ramon; Boudreau, Kevin; Mitchell, JordanCase HBS-708517-EThis case series looks at three important inflection points in Palm's history that relate to decisions about its platform: when the company was debating whether to open its operating system (OS) for licensing to third-party hardware manufacturers; 2001, when the company was deciding whether to split into two separate companies; and, 2005, when the company was migrating from its own OS into Linux. (The last part, set in 2008, is an epilogue). By l...Starting at €5.74
-
Linux vs. Windows, Teaching Note
Casadesus-Masanell, RamonTeaching Note HBS-709431-EStrategyTeaching Note for [707465].Starting at €0.00
-
Imprimis (B)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717496-EEntrepreneurshipThis case is a supplement to Imprimis (Case A). It describes the company's decision to enter into the pharmaceutical compounding business in 2013-14. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients' eyes post-cataract surgery, with the aim of replacing a complex regimen of prescription eye drops. After a successful launch of the compounded medication, Imprimis ran into complica...Starting at €5.74